Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PRCS -- Ignore unavailable to you. Want to Upgrade?

To: Mark Bong who wrote (15)	1/21/2001 2:52:17 PM
From: Spekulatius	Read Replies (1) \| Respond to of 78

Medscape - Abarelix This is an interesting article about hormone treatment of prostate cancer in Medscape (registration required but free). This article mentions Abarelix: medscape.com An excerpt: << Conclusions: A small but potentially important subgroup of men on depot LH-RH agonist therapy fail to achieve a castrate level of testosterone. Our findings support monitoring testicular response when LH-RH agonist therapy is initiated. >> It would be interesting to know if the non-response has been observed with Abarelix as well. If not,this would be another argument for Abarelix.